Previous 10 | Next 10 |
Lipocine (NASDAQ:LPCN): Q2 GAAP EPS of -$0.08 misses by $0.03. As of June 30, 2021, the Company had $46.6 million of unrestricted cash, cash equivalents, and marketable investments, compared to $19.7 million of unrestricted cash, cash equivalents and marketable investment securities as of Dec...
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2021 PR Newswire SALT LAKE CITY , Aug. 5, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today ...
NORTHBROOK, Ill., July 15, 2021 (GLOBE NEWSWIRE) -- Clarus and Lipocine (NASDAQ: LPCN) agreed to settle all outstanding claims in the patent infringement lawsuit brought against Clarus by Lipocine and to further resolve a patent interference between the parties. The action for patent infrin...
designer491/iStock via Getty Images Lipocine ([[LPCN]] -2.3%) has entered into a global settlement and license agreement with Clarus Therapeutics to resolve outstanding claims in an on-going intellectual property dispute. Terms of the settlement were not disclosed. Last month, Cantor Fitzgera...
Lipocine Announces Settlement With Clarus Therapeutics PR Newswire SALT LAKE CITY , July 14, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it has en...
Lipocine To Present At The Ladenburg Thalmann Healthcare Conference PR Newswire SALT LAKE CITY , July 6, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announc...
syahrir maulana/iStock via Getty Images Cantor Fitzgerald has initiated shares of Lipocine (LPCN) with an overweight rating and a $3 price target (~121% upside). The firm says the company has "multiple shots on goal across its metabolic and endocrine disorders pipeline over the next 12-18 mon...
Lipocine Announces Presentations at The International Liver Congress™ 2021 Digital Event PR Newswire SALT LAKE CITY , June 23, 2021 /PRNewswire/ -- Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine ...
Lipocine To Present At The Raymond James Human Health Innovation Conference PR Newswire SALT LAKE CITY , June 16, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, toda...
Lipocine (LPCN) jumps 9% premarket after announcing that the FDA has cleared its IND application to initiate a Phase 2 study to evaluate the therapeutic potential of LPCN 1154, an oral neuro-steroid product candidate, for the treatment of postpartum depression ((PPD)) in adults. A p...
News, Short Squeeze, Breakout and More Instantly...
2024-07-27 02:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study PR Newswire Met standard bioequivalence (BE) criteria C max, AUC 0-t , and AUC 0- ∞ C trough criterion was met LPCN 1154 was well tolerat...
Shares of Lipocine Inc. (NASDAQ: LPCN) traded at a new 52-week high today and are currently trading at $8.96. So far today, approximately 78,318 shares have been exchanged, as compared to an average 30-day volume of 32,701 shares. Lipocine Inc., a clinical-stage biopharmaceutical company, foc...